Editorial, FranceFrance

Biotechnology for sustainable growth

20.09.2009

The present crisis marks a major breaking point in the growth model and the financial fundamentals upon which mature economies are based. It has raised important issues concerning value creation, innovation and – above all – the sustainability of European national economies. Is our growth and development model nothing more than a mirage? Will we be able to achieve sustainable growth someday? How can we build strong competitive advantages, while at the same time dealing with demographic and environmental pressures?



Biotechnology represents the largest reservoir of scientific business innovation for the French economy, as well as for Europe’s economy as a whole. Our industry now has a unique opportunity to play a key role in the definition of new, post-crisis economic and social paradigms. Ultimately, biotech is a source of sustainable, responsible growth. First of all because sustainability is an inherent part of our sector’s growth models; many discoveries still lie ahead. These new discoveries are the key link in the chain of competitive advantages European economies must grab on the global level. Secondly, our companies are working towards socially responsible and environmentally friendly economic growth. Bio­logy is “sustainable growth” by definition, as it is recyclable and not based on commodities and imports. It delivers genuine solutions for human well-being and progress in a context marked by the growth of the global population, and provides solutions for major challenges in both energy sources and use.
France Biotech is pursuing three objectives in its contributions to the development of bio­technology. The French state’s strategic investment fund (FSI) and France Biotech have just entered into an agreement aimed at creating a lead investor for breakthrough technologies, putting tens of millions of euros into three or four cutting-edge projects that can be turned into strategic technology and business advantages. This is also a possible model for a European initiative.
The second target is France’s National Research Agency (ANR), which needs to double its present budget if it is to match proportionally the scope of the NIH. We have very good researchers and we need solid, validated innovations. When a research group succeeds in identifying a new “seam”, we need to give them enough resources to fully exploit it, and recruit additional research staff by offering excellent facilities and internationally competitive salaries.
The third key objective is to maintain the “Young Innovative Company” (YIC) fiscal status, which must stay focused on true innovation. “Innovation” must remain the preserve of breakthroughs capable of generating a commercial monopoly.
Modern biotechnology is a very young field that needs time to mature. Results can take many years to achieve. At other critical junctures, France and Europe were smart enough to set early priorities in trains, aerospace and nuclear energy – so why not in the life sciences as well?

FranceFrance

05.01.2012

Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/biotechnology-for-sustainable-growth.html

Product of the week

Products

Events

All Events

Current issue

All issues